ArticleJournal of surgical oncology2026
Outcomes of Total Pancreatectomy Versus Pancreaticoduodenectomy for Surgical Management of Pancreatic Ductal Adenocarcinoma.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients diagnosed with pancreatic ductal adenocarcinoma (PDAC) have a poor prognosis. Surgical resection provides the highest chance of improved survival. This study investigates the role of total pancreatectomy (TP) in the surgical management of PDAC based on clinicopathologic characteristics and the effect these factors have on patients' outcomes.
methodsData from the National Cancer Database for patients undergoing TP or pancreaticoduodenectomy (PD) was analyzed. Statistical tests included Chi-square test, logistic regression, least squared means, and Cox proportional hazard model to determine frequency and percentage, odds ratios, and hazard ratio, respectively.
resultsOf patients receiving PDAC resection, more TP patients were uninsured. Tumors in the pancreatic body or an overlapping locations increase the odds of receiving TP. Most statistically significant differences in clinicopathologic characteristics between the groups were not clinically meaningful. Despite a slight increase in short-term mortality for stage 2 patients receiving a TP, there was no clinically meaningful difference in overall survival.
conclusionTP conferred a minimally worsened short-term survival for stage 2 PDAC, but oncologic outcomes and OS were similar for TP and PD. Therefore, surgical approach should be guided by individual patient characteristics and comorbidities, as long-term oncologic outcomes between the two procedures are comparable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.